670256-21-0

Basic information

• Product Name: BENZOIC ACID, 4-BROMO-2-(HYDROXYMETHYL)-
• Synonyms: BENZOIC ACID, 4-BROMO-2-(HYDROXYMETHYL)-;4-BroMo-2-(hydroxyMethyl)benzoic acid;4-Bromo-alpha-hydroxy-o-toluic acid
• CAS NO: 670256-21-0
• Molecular Formula: C₈H₇BrO₃
• Molecular Weight: 231.044
• Mol File: 670256-21-0.mol

Chemical Properties

• Boiling Point: 383.053 °C at 760 mmHg
• Flash Point: 185.464 °C
• Appearance: /
• Density: 1.751 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: BENZOIC ACID, 4-BROMO-2-(HYDROXYMETHYL)-(CAS DataBase Reference)
• NIST Chemistry Reference: BENZOIC ACID, 4-BROMO-2-(HYDROXYMETHYL)-(670256-21-0)
• EPA Substance Registry System: BENZOIC ACID, 4-BROMO-2-(HYDROXYMETHYL)-(670256-21-0)

Safety Data

• Hazardous Substances Data: 670256-21-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BENZOIC ACID, 4-BROMO-2-(HYDROXYMETHYL)is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
BENZOIC ACID, 4-BROMO-2-(HYDROXYMETHYL)is also utilized as an intermediate in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural products.
Used in Organic Synthesis:
BENZOIC ACID, 4-BROMO-2-(HYDROXYMETHYL)serves as a building block in the synthesis of other chemical compounds, expanding its applications in the field of organic chemistry.

Upstream product

• 64169-34-2 5-bromophthalide 
• 65399-05-5 5-amino-3H-isobenzofuran-1-one 
• 67-56-1 methanol 
• 19477-73-7 6-bromophthalide 

Downstream Products

• 871502-87-3 4-bromo-2-formylbenzoic acid 
• 1256845-46-1 4-bromo-2-((tert-butyldimethylsilyloxy)methyl)benzoic acid 
• 168759-64-6 7-bromoisochroman-4-one 
• 1337154-53-6 7-bromoisochroman-4-amine 
• 1361938-13-7 methyl 4-bromo-2-(methoxymethyl)benzoate 
• 882993-87-5 4-bromo-2-(methoxymethyl)benzoic acid 
• 1361938-42-2 C₁₀H₁₁BrO₃ 
• 1361938-37-5 C₁₅H₁₃BrO₃ 
• 1361938-07-9 2-methyl-2-propanyl 4-bromo-2-(methoxymethyl)benzoate 
• 1361938-40-0 C₈H₅BrF₂O₂ 
• 1361938-39-7 C₁₅H₁₁BrF₂O₂ 
• 1361938-38-6 C₁₅H₁₁BrO₃ 

Relevant articles and documents

HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF

The present invention relates to a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the treatment of various HAT-related diseases or conditions.

Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1

Primary hyperoxaluria type 1 (PH1) is a rare life-threatening genetic disease related to glyoxylate metabolism and characterized by accumulation of calcium oxalate crystals. Current therapies involve hepatic and/or renal transplantation, procedures that have significant morbidity and mortality and require long-term immunosuppression. Thus, a pharmacological treatment is urgently needed. We introduce here an unprecedented activity of salicylic acid derivatives as agents capable of decreasing oxalate output in hyperoxaluric hepatocytes at the low micromolar range, which means a potential use in the treatment of PH1. Though correlation of this phenotypic activity with glycolate oxidase (GO) inhibition is still to be verified, most of the salicylic acids described here are GO inhibitors with IC50 values down to 3 μM. Binding mode of salicylic acids inside GO has been studied using in silico methods, and preliminary structure-activity relationships have been established. The drug-like structure and ease of synthesis of our compounds make them promising hits for structural optimization.

PPAR (peroxisome proliferator-activated receptor) agonist and application thereof to treatment of senile dementia and other diseases

The invention relates to a compound, namely a gamma-subtype peroxisome proliferator-activated receptor (PPAR) agonist. In addition, the invention discloses a medicinal component and a preparation containing the compound and application of such the gamma-subtype PPAR agonist.

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

CYCLIC AMIDE DERIVATIVE

Provided is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, A is C6-10 arylene, etc.; R1a, R1b and R1c each independently is a hydrogen atom, a halogen atom, a C1-4 alkyl group, a C1-4 alkoxy group, etc.; R2 is an optionally substituted C6-10 aryl group, an optionally substituted 5- to 12-membered monocyclic or polycyclic heteroaryl group, an optionally substituted C7-16 aralkyl group, etc.; m is 0, etc.; n is an integer of 0 to 2.)

Enantioselective copper-catalyzed intramolecular O-H insertion: An efficient approach to chiral 2-carboxy cyclic ethers

A copper-catalyzed asymmetric intramolecular O-H insertion of ω-hydroxy-α-diazoesters has been accomplished by using chiral spiro bisoxazoline ligands. This highly enantioselective intramolecular O-H insertion reaction provides an efficient approach to a

NEW COMPOUNDS I/418

There is provided compounds of formula I, wherein R1 to R7 have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.